Sucampo Pharmaceuticals, Inc.
SCMP
SCMP was delisted on the 12th of February, 2018.
178 hedge funds and large institutions have $360M invested in Sucampo Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 68 increasing their positions, 48 reducing their positions, and 17 closing their positions.
286% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $309K
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
42% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 48
32% more capital invested
Capital invested by funds: $272M → $360M (+$87.6M)
7% more funds holding
Funds holding: 167 → 178 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.9M |
| 2 |
Goldman Sachs
New York
|
+$7.15M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$6.97M |
| 4 |
Renaissance Technologies
New York
|
+$5.55M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$4.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$4.22M |
| 2 |
Millennium Management
New York
|
-$2.61M |
| 3 |
HHC
Hutchin Hill Capital
New York
|
-$1.14M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$975K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$954K |
SCMP Hedge Fund Activity: Q3 2017 in Review
178 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q3 2017, worth a combined $360M — up 32% from $272M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SCMP positions and 17 closed out — a net gain of 13 holders — while 68 added to existing stakes and 48 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $20.9M. The largest seller was Rubric Capital Management (New York), cutting an estimated $4.22M.
- 178 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q3 2017, up from 167 in Q2 2017.
- Funds reported $360M of Sucampo Pharmaceuticals, Inc. stock for Q3 2017, up 32% quarter-over-quarter.
- 30 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q3 2017 and 17 closed out, a net change of +13 holders.
- The largest Sucampo Pharmaceuticals, Inc. buyer in Q3 2017 was Point72 Asset Management, an estimated $20.9M added.
- The largest Sucampo Pharmaceuticals, Inc. seller in Q3 2017 was Rubric Capital Management (New York), an estimated $4.22M sold.
Based on aggregated 13F filings for Q3 2017.